Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

@article{Wu2017DacomitinibVG,
  title={Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.},
  author={Yi-Long Wu and Ying Cheng and Xiangdong Zhou and Ki Hyeong Lee and Kazuhiko Nakagawa and Seiji Niho and Fumito Tsuji and Rolf Gerhard Linke and Rafael Rosell and Jes{\'u}s Perea Corral and Maria Rita Migliorino and Adam Pluzanski and Eric I. Sbar and Tao Wang and Jane Liang White and Sashi Nadanaciva and Rickard Sandin and Tony Shu Kam Mok},
  journal={The Lancet. Oncology},
  year={2017},
  volume={18 11},
  pages={
          1454-1466
        }
}
BACKGROUND Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 54 CITATIONS, ESTIMATED 39% COVERAGE

Dacomitinib: First Global Approval

  • Drugs
  • 2018
VIEW 13 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Marscha S Holleman, Harm van Tinteren, Harry J. M. Groen, Maiwenn J. Al, Carin A Uyl-de Groot
  • OncoTargets and therapy
  • 2019
VIEW 6 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

Patient-reported outcomes in a phase II study of alectinib

  • ESMO open
  • 2018
VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.

  • Translational lung cancer research
  • 2018
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Clinical development of targeted and immune based anti-cancer therapies

  • Journal of experimental & clinical cancer research : CR
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2017
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 19 Citations per year over the last 3 years

  • 84% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Similar Papers

Loading similar papers…